(redirected from delayed graft)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia.


A colloquial term referring to the unlawful acquisition of public money through questionable and improper transactions with public officials.

Graft is the personal gain or advantage earned by an individual at the expense of others as a result of the exploitation of the singular status of, or an influential relationship with, another who has a position of public trust or confidence. The advantage or gain is accrued without any exchange of legitimate compensatory services.

Behavior that leads to graft includes Bribery and dishonest dealings in the performance of public or official acts. Graft usually implies the existence of theft, corruption, Fraud, and the lack of integrity that is expected in any transaction involving a public official.


noun blackmail, bribery, corruption, fraudulent income, hush money, illegal profit, illicit profit, illicit revenue, inserere, kickback, money illegally accuired, political corruption, profiteering, property illegally acquired, unjust acquisition, unlawful gain
Associated concepts: bribery, corruption, official misconduct
See also: bribe, connect, corruption, crime, gratuity, hush money, improbity, spoils

GRAFT. A figurative term in chancery practice, to designate the right of a mortgagee in premises, to which the mortgagor at the time of making the mortgage had an imperfect title, but who afterwards obtained a good title. In this case the new mortgage is considered a graft into the old stock, and, as arising in consideration of the former title. 1 Ball & Beat. 46; Id. 40; Id. 57; 1 Pow. on Mortg. 190. See 9 Mass. 34. The same principle has obtained by legislative enactment in Louisiana. If a person contracting an obligation towards another, says the Civil Code, art. 2371, grants a mortgage on property of which he is not then the owner, this mortgage shall be valid, if the debtor should ever acquire the ownership of, the property, by whatever right.

References in periodicals archive ?
Effect of various histological changes on graft function at 1 month Histological changes if Number of Effect on graft function cortical biopsy patients (out of 84) Normal histology 48 (58%) No effect Glomerulosclerosis 21 (25%) No effect Interstitial fibrosis 11 (13%) Delayed graft function: 4 Acute tubular necrosis 4 (5%) Acute rejection: 2 Delayed graft function: 2 Focal tubal atrophy 4 (5%) No effect Table 2.
A risk prediction model for delayed graft function in the current era of deceased donor renal transplantation.
Serum neutrophil gelatinase-associated lipocalin and interleukin-18 as predictive biomarkers for delayed graft function after kidney transplantation.
Delayed graft function in patients following hand-assisted laparoscopic donor nephrectomy and open living-donor nephrectomy Donor nephrectomy Hand-assisted laparoscopic donor nephretcomy (n = 35) * Delayed graft function [1 (3%)] Ruptured kidney (1) Open living-donor nephrectomy (n = 65) ** Delayed graft function [5 (8%)] Postoperative bleeding (2) Hyperacute rejection (1) Infarction in the kidney (1) Ureteric obstruction (1) Postoperative bleeding (2)
In our case, the elevated urinary markers were associated with acute Tac nephrotoxicity and not AR or delayed graft function as previous studies on kidney allografts pointed out.
Following successful completion of the phase 1 trial, the company plans to conduct a two-part multi-centered, double blinded and placebo controlled clinical study to evaluate the safety, tolerability and efficacy of OPN-305 in renal transplant patients at high risk of Delayed Graft Function (DGF) as the first clinical target indication for the development of OPN-305 to be initiated in 2012.
Transplant Genomics (TGI), a molecular diagnostic company, and Israel-based Quark Pharmaceuticals are pursuing a discovery and development collaboration involving the use of TGI's TruGraf blood test in a Phase three clinical trial involving patients being treated for delayed graft function with Quark's proprietary drug candidate, QPI-1002, it was reported on Friday.
We also believe there is a significant learning curve in managing the DCD donor/organ and that delayed graft function (DGF) rates fall with increasing clinical experience.
Fremont, CA, announced the European Commission has graphed Orphan Medicinal Product Designation for QPI-1002 (also referred to as I5NP) for the prophylaxis of delayed graft function (DGF) in kidney transplant recipients.
had several predisposing factors that have been implicated in premature transplant loss, including donor age greater than 50 years old, delayed graft function, acute rejection episodes, elevated serum lipid levels, and cytomegalovirus infection (Mudge, Carlson, & Brennan, 1998).
antibody-mediated rejection (AMR) and delayed graft function (DGF) following kidney transplantation.
Alexion Pharmaceuticals, the original developer and distributor of Soliris (eculizumab), has been granted orphan drug designation for the drug by the US Food and Drug Administration (FDA) for the prevention of delayed graft function (DGF) in renal transplant patients, it was reported yesterday.

Full browser ?